Take part in the 4th edition of the Transatlantic Exchanges dedicated to radioligand therapies

Gustave Roussy and the Dana-Farber Cancer Institute (Boston, United States) are organising the fourth edition of the Transatlantic Exchange oncology conference on 19 March 2025 at the Hyatt Regency Paris Étoile hotel. The theme will be “Radiopharmaceutical Therapy Meets Oncology.”

Free registration (in-person or virtual): https://events.medscapelive.org/website/82041/.

After the 2024 edition dedicated to liquid biopsy, organised in Boston, the Franco-American oncology conference Transatlantic Exchange returns this year to Paris to discuss the latest advances related to radioligand therapies.

Physician-researchers will share their expertise on theranostics for early cancer detection and characterisation, the latest clinical advances concerning innovative radiopharmaceuticals, and the prospects for the development of radioligand treatments.

A radioligand treatment, or radionuclide therapy, is an innovative approach in oncology that combines a drug specifically targeting tumour cells with a radioactive isotope. This therapy delivers a radiation dose directly to cancer cells while sparing healthy tissues, offering increased precision and new perspectives for treating numerous cancers.

This edition of the Transatlantic Exchange will be chaired by Professor Toni Choueiri, Medical Director of International Strategic Initiatives and Director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, as well as by Professor Karim Fizazi, Head of the International Academic Network at Gustave Roussy and Head of the Genitourinary Cancer Committee at the Institute.

Registrations open

The conference, organised with the support of the Institut Servier and Medscape Medical Affairs, is free and open to healthcare professionals interested in oncology.

Registration on the website: https://events.medscapelive.org/website/82041/.